on SynBiotic SE (isin : DE000A3E5A59)
SYNBIOTIC Advances in Medical Cannabis and Hemp Sectors in 2026
SYNBIOTIC SE continues its strategic progress in the medical cannabis and industrial hemp sectors into spring 2026, backed by operational successes and regulatory advances. The company’s subsidiary, GOC Nexus, has launched operations, driven by a new GMP certification from the German Federal Institute for Drugs and Medical Devices. Holding a 15.1% stake in GOC with potential increases, SYNBIOTIC supports high-scale cannabis supply with innovative processing technologies.
In Germany, legal cannabis markets continue to grow. The EKOCAN interim report highlights significant shifts to legal channels and estimates an available medical cannabis volume of nearly 200 tons for 2025. Political movements, such as a hemp liberalization bill, add momentum, aiming to boost industrial hemp market and sustainability.
SYNBIOTIC's presence at industry events like ICBC Berlin further underscores its commitment to market leadership. The focus is on regulatory discussions and growth strategies as Germany positions itself as a central player in the cannabis market.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SynBiotic SE news